Biogen gains over 1 billion in capitalization thanks to Alzheimer’s pipeline

One billion dollars in capitalization – this is what Biogen gained yesterday as the investment bank Goldman Sachs added the US-based biotech to its Equity Conviction List, including the companies with the best growth potential. Biogen’s inclusion on the list reflects the high potential of the investigational Alzheimer’s therapy aducanumab, the report by Goldman Sachs says. Aducanumab is still undergoing Phase III clinical trial. It targets amyloid plaques, which cause the condition. Aducanumab is likely to be launched in Q4 2019 and has potential to generate $12bn, Goldman Sachs’ analysts say. Alzheimer’s and other types of dementia have an extremely high social cost, which will reach $1,000bn globally in 2017.
(Source: Boston Business Journal)